In light of the news today curious what folks think the impact will be with Humira accounting for 1/3 of their revenue. I’m worried it could accelerate decline in revenue unless other drugs make up for that loss which we are starting to see with some of their immunologics. Now I’m wondering if this is a yield trap for the foreseeable future with their dividend. If Epkinly can become the blockbuster that it could be these fears could be overblown. Quite a competitive sector pharmaceutical is. 🍻

https://www.cnbc.com/amp/2023/08/23/cvs-health-sandoz-humira-biosimilar.html